IFN-β and glatiramir acetate are the most widely used licensed disease-modifying treatments in MS. There is a consensus that they are acceptably safe and have partial efficacy, reducing the relapse ...

Allogeneic hematopoietic cell transplantation (HCT) is a commonly used curative therapy for individuals with inborn errors of immunity (IEI). HCT involves introducing stem cells from a compatible ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Full results of phase 3 trials of alemtuzumab (Lemtrada, Genzyme/Sanofi) confirm that treatment was associated with reductions in relapse rates in patients with relapsing-remitting multiple sclerosis ...

Cellectis demonstrated that the addition of alemtuzumab to the lymphodepletion regimen was associated with prolonged lymphodepletion and significantly higher cell expansion and clinical activity In ...

AML is a cancer of the haematopoietic stem and progenitor cells resulting in a long-lasting leukaemic stem cell clone that is frequently resistant to standard ...

Alemtuzumab (Campath-1H) is a humanized IgG1 monoclonal antibody that targets the human CD52 antigen. CD52 is expressed by a variety of lymphoid neoplasms and most human mononuclear cell subsets. In ...

Fatal adverse events (AEs) associated with alemtuzumab for multiple sclerosis (MS) may occur more frequently than previously understood based on past published literature, researchers found. Patients ...

Alemtuzumab improved clinical and magnetic resonance imagining outcomes in patients with relapsing-remitting multiple sclerosis across varying age groups and maintained efficacy through year 8 of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

PARIS, May 11, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – Euronext Growth: ALCLS), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in ...